Back to today’s briefing

Story perspectives

Abbott Reports Q4 Gains, Eyes Future Growth and Acquisition

1/22/2026

50 7 Full Breakdown

Summary

Story summary

Abbott Laboratories reported Q4 and full-year 2025 results, with revenue of $11.459 billion and adjusted diluted earnings per share (EPS) of $1.50, a 4.4% increase from 2024.
Abbott missed revenue expectations, but its operating margin rose to 19.6%.
For 2026, Abbott projects organic sales growth of 6.5% to 7.5% and adjusted diluted EPS of $5.55 to $5.80.
Abbott plans to acquire Exact Sciences to boost cancer diagnostics.

1 of 1

Story summary

Abbott Laboratories reported Q4 and full-year 2025 results, with revenue of $11.459 billion and adjusted diluted earnings per share (EPS) of $1.50, a 4.4% increase from 2024.
Abbott missed revenue expectations, but its operating margin rose to 19.6%.
For 2026, Abbott projects organic sales growth of 6.5% to 7.5% and adjusted diluted EPS of $5.55 to $5.80.
Abbott plans to acquire Exact Sciences to boost cancer diagnostics.